The Nineteenth International Conference on Endothelin (ET-19)
About the International Conference on Endothelin (ET-19)
More than 35 years ago, the Japanese physician-scientist Tomoh Masaki (1934-2020) discovered endothelins and endothelin receptors at the University of Tsukuba between 1987 and 1990. The scientific advances and new patient treatments resulting from Professor Masaki's discoveries are summarized in Endothelin - 30 years from discovery to therapyIn memoriam: Tomoh Masaki.
Conference Details and Deadlines
-
Abstracts and Presentations
Abstracts and Presentations
The Nineteenth International Conference on Endothelin (ET-19) committee requests for abstracts for Oral and Poster Presentations from across the spectrum of ET-19 research.
Submission Deadline: June 30, 11:59 PM CT
Categories:
- Nephrology
- Oncology
- Vascular Biology/Hypertension
- Neurology
- Inflammation/Rheumatology
- Women's Health
- Cardiology and Pulmonology
- Endocrinology
- Clinical Trials and Health Barriers
Parameters:
All abstracts are to be submitted by the deadline and are limited to 1400 Characters (not including the abstract's title, name, and affiliation of authors).Submissions:
All will be submitted through a form based submission. Please complete in a Word document to copy and paste into the submission fields. Please click the link below for all abstract submissions. By submitting the abstract, the submitter confirms that all authors have approved the abstract that her the research has adhered to rigorous and reproducibility requirements.
Abstract Submission FormOpens an external link. -
General Agenda
General Agenda
Sunday, September 21, 2025
5:00 PM - 7:00 PM: Welcome Reception
Monday, September 22, 2025
7:30 AM - 8:30 PM: Conference Proceedings; Location: Francis Marion Hotel and Conference Center
Opening Lecture: David Webb
University of Edinburgh, United KingdomSession I: Nephrology
Keynote Lecture: Vimal Derebail, MD
University of North Carolina at Chapel HillSession II: Cancer: Maneesh Jain, PhD
University of Nebraska Medical CenterSession III: Vascular Biology and Hypertension
Keynote Lecture: Jennifer Pollock, PhD
University of Alabama at BirminghamTuesday, September 23, 2025
7:00 AM - 5:00 PM: Conference Proceedings; Location: Francis Marion Hotel and Conference Center
Session IV: Neurology
Keynote Lecture: TBDSession V: Inflammation/Rheumatology
Keynote Lecture: Erin Taylor, PhD
University of Mississippi Medical CenterSection VI: Women’s Health
Keynote Lecture: Michelle Gumz, PhD
University of FloridaSession VII: Cardiology
Keynote Lecture: Rajat Gupta, MD
Harvard Medical SchoolWednesday, September 24, 2025
7:00 AM 2:45 PM: Conference Proceedings; Location: Francis Marion Hotel and Conference Center
Session VIII: Endocrinology/Metabolism
Keynote: TBDSession IX: Clinical Trials
Keynote Lecture: TBDSession X: Panel Discussion: Recent Clinical Trials and the Future of ET-1 Receptor Antagonists in Clinical Care
Moderator: Donald Kohan, MD, PhD
University of UtahSession XI: Concluding Remarks
Masashi Yanagisawa, MD, PhD
University of Tsukuba, Tsukuba, Japan -
Conference Registration
Conference Registration
Register Here
Details:All Trainees: $250
All Faculty and Industry/Pharmaceutical: $500
Early Bird Registration Ends on July 31, 2025 at 11:59 PM
Meet the Organizers
Dr. Malgorzata Kasztan
Assistant Professor, Division of Hematology
University of North Carolina
Learn More
Dr. Joshua Speed
Associate Professor, Department of Physiology and Biophysics
The University of Mississippi Medical Center
Learn More
Dr. Justin Van Beusecum
Assistant Professor, Department of Medicine
Medical University of South Carolina
Learn More
Thanks to our Sponsors
-
UAB Cardio-Renal Physiology and Medicine
Department of Medicine, Division of Nephrology, Section of Cardio-Renal Physiology
From investigating the molecular mechanisms underlying cardiovascular and renal diseases to developing novel therapies and interventions, our faculty, students, fellows, and staff are dedicated to advancing the field and improving outcomes for patients.
Learn More -
Pharmazz Inc.
Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies
-
Travere Therapeutics
"The science we are advancing in rare kidney and metabolic disease has the potential to set new standards of care and bring hope to people with these rare disorders."
